Tech Firms Prepare for the Worst

However, Steve Burrill, a venture capitalist specializing in biotech , is less sanguine. "This is a massive reorganization of capital market structures," he says. "Over the last 40 years, capital has been reasonably available, reasonably cheap, and reasonably consistent. In the future, none of that is going to be true."